# Insmed Incorporated (INSM) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $104.44, market value $22.9 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Insmed Incorporated reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 15.1×**. Each dollar of revenue is priced at 15.1×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 31.5×**. The shares trade at 31.5× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -2.7%** (5-yr avg -10.1%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -37.1%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -210.5%**. The company reported a net loss over the last twelve months.
- **Return on equity: -172.8%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -57.9%**. Return on all capital, debt included, is -57.9%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -26.7%**. Each dollar of assets produces -26.7% of profit.

## Growth
- **Revenue growth (1 yr): 66.7%** (3-yr 35.2%/yr, 5-yr 29.8%/yr). Revenue grew 66.7% over the last year, against 29.8% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): -15.3%**. Earnings per share fell 15.3%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.73**. Debt is 0.73 times equity, moderate leverage.
- **Current ratio: 3.83** (quick 3.83). Current assets cover the next year's liabilities 3.83 times.
- **Altman Z-score: 8.62**. A Z-score of 8.62 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Insmed Incorporated does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (22 analysts). 22 analysts cover Insmed Incorporated; the consensus is strong_buy, with an average price target of $193.95 (+86% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -42.3%** (YTD -37.2%, 3-mo 11.0%). The shares are down 42.3% over twelve months including dividends.
- **From 52-week high: -50.9%** (15.5% above the low). Trading 51% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 57**. An RSI of 57 is neutral.
- **Beta (1 yr): 0.48** (volatility 62%). Beta of 0.48 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=INSM · Page: https://foliofundamentals.com/stocks/insm

Not investment advice.